Cargando…

Expression of tumor-associated antigens in breast cancer subtypes

OBJECTIVES: Tumor-associated antigens (TAAs) are frequently overexpressed in several cancer types. The aim of this study was to investigate the expression of TAAs in breast cancer. MATERIAL AND METHODS: A total of 250 selected invasive breast cancers including 50 estrogen receptor (ER)-positive (Lum...

Descripción completa

Detalles Bibliográficos
Autores principales:	Curigliano, Giuseppe, Bagnardi, Vincenzo, Ghioni, Mariacristina, Louahed, Jamila, Brichard, Vincent, Lehmann, Frederic F., Marra, Antonio, Trapani, Dario, Criscitiello, Carmen, Viale, Giuseppe
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2019
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7375652/ https://www.ncbi.nlm.nih.gov/pubmed/31869767 http://dx.doi.org/10.1016/j.breast.2019.12.002

Ejemplares similares

Practical classification of triple-negative breast cancer: intratumoral heterogeneity, mechanisms of drug resistance, and novel therapies
por: Marra, Antonio, et al.
Publicado: (2020)

Predicting Response to Antibody Drug Conjugates: A Focus on Antigens’ Targetability
por: Ascione, Liliana, et al.
Publicado: (2023)

Toward precision medicine in inflammatory breast cancer
por: Viale, Giulia, et al.
Publicado: (2019)

Impact of autoimmune diseases on outcome of patients with early breast cancer
por: Criscitiello, Carmen, et al.
Publicado: (2016)

Profile of buparlisib and its potential in the treatment of breast cancer: evidence to date
por: Criscitiello, Carmen, et al.
Publicado: (2018)

The experience on coronavirus disease 2019 and cancer from an oncology hub institution in Milan, Lombardy Region
por: Trapani, Dario, et al.
Publicado: (2020)

Recent advances in triple negative breast cancer: the immunotherapy era
por: Marra, Antonio, et al.
Publicado: (2019)

Mismatch Repair Deficiency as a Predictive Biomarker for Immunotherapy Efficacy
por: Viale, Giulia, et al.
Publicado: (2017)

PIK3CAMutations in Breast Cancer Subtypes Other Than HR-Positive/HER2-Negative
por: Ascione, Liliana, et al.
Publicado: (2022)

Highlights from the 14(th) St Gallen International Breast Cancer Conference 2015 in Vienna: Dealing with classification, prognostication, and prediction refinement to personalize the treatment of patients with early breast cancer
por: Esposito, Angela, et al.
Publicado: (2015)

Accelerating progress in early triple-negative breast cancer: A viewpoint on antibody-drug conjugates, back from St Gallen breast cancer conference 2021()
por: Trapani, Dario, et al.
Publicado: (2021)

Tumor Infiltrating Lymphocytes across Breast Cancer Subtypes: Current Issues for Biomarker Assessment
por: Valenza, Carmine, et al.
Publicado: (2023)

HER2 Low, Ultra-low, and Novel Complementary Biomarkers: Expanding the Spectrum of HER2 Positivity in Breast Cancer
por: Venetis, Konstantinos, et al.
Publicado: (2022)

Barriers to the Use of Trastuzumab for HER2+ Breast Cancer and the Potential Impact of Biosimilars: A Physician Survey in the United States and Emerging Markets
por: Lammers, Philip, et al.
Publicado: (2014)

Antibody–drug conjugates in solid tumors: a look into novel targets
por: Criscitiello, Carmen, et al.
Publicado: (2021)

Highlights from the 13th St Gallen International Breast Cancer Conference 2013. Access to innovation for patients with breast cancer: how to speed it up?
por: Curigliano, Giuseppe, et al.
Publicado: (2013)

COVID-19 vaccines in patients with cancer
por: Trapani, Dario, et al.
Publicado: (2021)

Master protocols in immuno-oncology: do novel drugs deserve novel designs?
por: Mazzarella, Luca, et al.
Publicado: (2020)

Conducting phase 1 cancer clinical trials during the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)–related disease pandemic
por: Tarantino, Paolo, et al.
Publicado: (2020)

Best management of locally advanced inoperable breast cancer
por: Curigliano, Giuseppe, et al.
Publicado: (2013)

Targeting Post-Translational Modifications to Improve Combinatorial Therapies in Breast Cancer: The Role of Fucosylation
por: Antonarelli, Gabriele, et al.
Publicado: (2023)

Immune Checkpoint Blockade in Cancer Treatment: A Double-Edged Sword Cross-Targeting the Host as an “Innocent Bystander”
por: Gelao, Lucia, et al.
Publicado: (2014)

Opportunities and challenges of implementing Pharmacogenomics in cancer drug development
por: Tarantino, Paolo, et al.
Publicado: (2019)

Immune approaches to the treatment of breast cancer, around the corner?
por: Criscitiello, Carmen, et al.
Publicado: (2014)

Are all cyclin-dependent kinases 4/6 inhibitors created equal?
por: Marra, Antonio, et al.
Publicado: (2019)

A Comprehensive Preclinical Model Evaluating the Recombinant PRAME Antigen Combined With the AS15 Immunostimulant to Fight Against PRAME-expressing Tumors
por: Gérard, Catherine, et al.
Publicado: (2015)

Loss of HER2 in breast cancer: biological mechanisms and technical pitfalls
por: Morganti, Stefania, et al.
Publicado: (2022)

Evolving treatment landscape of immunotherapy in breast cancer: current issues and future perspectives
por: Valenza, Carmine, et al.
Publicado: (2023)

Proposed new clinicopathological surrogate definitions of luminal A and luminal B (HER2-negative) intrinsic breast cancer subtypes
por: Maisonneuve, Patrick, et al.
Publicado: (2014)

Management of Cardiac Toxicity Induced by Chemotherapy
por: Trapani, Dario, et al.
Publicado: (2020)

Incorporating clinicopathological and molecular risk prediction tools to improve outcomes in early HR+/HER2– breast cancer
por: Curigliano, Giuseppe, et al.
Publicado: (2023)

Tips and Tricks for Early Diagnosis of Cervico-Vaginal Involvement from Extramammary Paget’s Disease of the Vulva: A Referral Center Experience
por: Iacobone, Anna Daniela, et al.
Publicado: (2023)

Solitary breast neurofibroma: imaging aspects
por: Rotili, Anna, et al.
Publicado: (2018)

Unlocking the Resistance to Anti-HER2 Treatments in Breast Cancer: The Issue of HER2 Spatial Distribution
por: Giugliano, Federica, et al.
Publicado: (2023)

Prognosis of selected triple negative apocrine breast cancer patients who did not receive adjuvant chemotherapy
por: Montagna, Emilia, et al.
Publicado: (2020)

Safety of COVID-19 mRNA Vaccines in Patients with Cancer Enrolled in Early-Phase Clinical Trials
por: Trillo Aliaga, Pamela, et al.
Publicado: (2021)

European Society for Medical Oncology (ESMO) 2018 Congress Twitter analysis: from ethics to results through the understanding of communication and interaction flows
por: Passaro, Antonio, et al.
Publicado: (2020)

Breast Cancer with Brain Metastasis: Molecular Insights and Clinical Management
por: Ivanova, Mariia, et al.
Publicado: (2023)

RNAi screens identify CHD4 as an essential gene in breast cancer growth
por: D'Alesio, Carolina, et al.
Publicado: (2016)

Immunosuppression and Multiple Primary Malignancies in Kidney-Transplanted Patients: A Single-Institute Study
por: Santangelo, Michele L., et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_dif6lifmj4dbu0geun7dcoi2lb